Vera Therapeutics (NASDAQ: VERA) experienced a notable increase in its stock price, closing 13% higher on Wednesday, following a positive analyst note. Cantor Fitzgerald’s Pete Stavropoulos maintained an overweight rating and set a price target of $100 per share, which is over three times the current share price. This endorsement significantly contributed to the stock’s rise. Vera continues to attract investor attention in the biotech sector.
